Table 1. Demographic and Clinical Characteristics of Subjects with HIV, Diabetes and both HIV and Diabetes.
| HIV+/Diabetes | HIV+ | Diabetes | p-value | |
| N | 73 | 82 | 61 | |
| Age (yrs) | 52±1 | 45±1 | 51±1 | <0.0001a0.9b<0.0001c |
| Race/ethnicity (%) | 0.0002 | |||
| African American | 74 | 38 | 67 | |
| Caucasian | 18 | 48 | 25 | |
| Hispanic | 5 | 7 | 8 | |
| Asian | 1 | 6 | 0 | |
| Other | 2 | 1 | 0 | |
| Sex (%) | 0.1 | |||
| % Male | 63 | 78 | 67 | |
| % Female | 37 | 22 | 33 | |
| BMI (kg/m2) | 31±1 | 26±1 | 35±1 | <0.0001a0.001b<0.0001c |
| Systolic BP (mmHg) | 131±2 | 123±1 | 127±3 | 0.002 a0.16 b0.13 c |
| Diastolic BP (mmHg) | 80±1 | 77±1 | 77±1 | 0.18 |
| ACE or ARB use (%) | 49% | 20% | 64% | <0.0001a0.09b<0.0001c |
| Duration diabetes (yrs) | 6.8±0.7 | 6.2±0.8† | 0.53 | |
| Current insulin use (%) | 29 | 21 | 0.32 | |
| Hemoglobin A1c | 7.1±0.2 | 7.8±0.3 | 0.03 | |
| Duration HIV (yrs) | 13±1 | 14±1 | 0.38 | |
| CD4 (cells/mL) | 588±32 | 522±30 | 0.13 | |
| HIV VL <50 copies/mL (%) | 56 | 81 | 0.0007 | |
| Current use ARV therapy (%) | 77 | 94 | 0.002 | |
| ARV therapy naïve (%) | 15 | 1 | 0.0006 | |
| Duration ARV therapy (yrs) | 7.7±0.6 | 7.9±0.5 | 0.8 | |
| Serum creatinine (mg/dL) | 0.96±0.02 | 0.98±0.02 | 0.94±0.02 | 0.45 |
| Glomerular Filtration Rate (mL/min) | 82.0±2.3 | 88.1±2.2 | 82.6±1.9 | 0.09 |
| Urinary albumin/creatinine ratio (mg/g) | 117.5±36.8 | 17.7±5.4 | 59.9±32.2 | <0.0001a0.1b0.04c |
†
data available on 43 subjects,
a
– p-value for HIV+ diabetes+ versus HIV+.
b
– p value for HIV+ diabetes+ versus diabetes+.
c
– p value for HIV+ versus diabetes+.